Nature Reviews Urology

Papers
(The H4-Index of Nature Reviews Urology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Novel intravesical gemcitabine delivery system (TAR-200) for neoadjuvant treatment of MIBC: context is everything214
Texture analysis for patient selection195
Single-cell and spatial sequencing of kidney cancer143
Human-relevant urothelial model provides insight into infection strategies and host response128
Krause corpuscles act as genital vibration detectors99
Semen quality recovery following COVID-1997
PARP inhibitors plus enzalutamide to treat mCRPC81
Urine microbiota differ in bladder cancer78
Preclinical models of bladder cancer: BBN and beyond76
Micro-ultrasound for prostate cancer75
High-dose chemotherapy for relapsed testicular germ cell tumours72
Time for women-centred gynaecology71
Advancing the state of the art in congenital obstructive uropathy69
Considering urology in a planetary context65
A clinical guide to rare male sexual disorders64
FOXA2–KIT-driven lineage plasticity in NEPC64
Proteomic-based analysis of testicular interstitial fluid64
Prevalence of gender dysphoria in Japan59
A new text message-based platform for self-management of patients with IC/BPS56
Promise without practice — charting the path forward for bladder cancer biomarkers53
Overcoming antibiotic resistance in complicated UTI53
Metaverse in surgery — origins and future potential51
Madrid plays host to a celebration of urology51
Microfluidic sperm selection50
What happens in Vegas … shapes the future of urology50
Hallmark discoveries in the biology of non-Wilms tumour childhood kidney cancers49
The evolving landscape of monogenic nephrolithiasis and therapeutic innovations49
Leveraging generative AI to enhance doctor–patient communication48
Evolution of the World Health Organization semen analysis manual: where are we?48
Antibiotic therapy for treating overactive bladder is not supported by clinical evidence46
Pembrolizumab + axitinib beyond first-line therapy for mRCC46
Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer46
A non-invasive assay for UTUC diagnosis45
COVID can’t kill CopMich collaboration44
The mechanism of action of neuromodulation in the treatment of overactive bladder42
Measuring and improving the cradle-to-grave environmental performance of urological procedures42
Vaccination to prevent untreatable gonorrhoea42
Resolving the puzzle of same-sex sexual interactions39
Quest for a genetic biomarker for sickle cell disease priapism: rationale, progress and implications39
0.14049077033997